Ranolazine for Angina in Hypertrophic Cardiomyopathy
Joint Authors
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-2, 2 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-04-15
Country of Publication
Egypt
No. of Pages
2
Main Subjects
Abstract EN
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL).
However, its use is limited mostly to patients with coronary artery disease.
However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy.
Hereby, we discuss two cases where ranolazine led to improvement in angina refractory to beta-blockers.
In conclusion, ranolazine can be considered as a potential antianginal drug in patients with hypertrophic cardiomyopathy refractory to beta-blockers.
American Psychological Association (APA)
Amin, Akhtar& Kim, Bernard. 2018. Ranolazine for Angina in Hypertrophic Cardiomyopathy. Case Reports in Cardiology،Vol. 2018, no. 2018, pp.1-2.
https://search.emarefa.net/detail/BIM-1140994
Modern Language Association (MLA)
Amin, Akhtar& Kim, Bernard. Ranolazine for Angina in Hypertrophic Cardiomyopathy. Case Reports in Cardiology No. 2018 (2018), pp.1-2.
https://search.emarefa.net/detail/BIM-1140994
American Medical Association (AMA)
Amin, Akhtar& Kim, Bernard. Ranolazine for Angina in Hypertrophic Cardiomyopathy. Case Reports in Cardiology. 2018. Vol. 2018, no. 2018, pp.1-2.
https://search.emarefa.net/detail/BIM-1140994
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1140994